The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers

AstraZeneca

Status and phase: Completed; Early Phase 1

Conditions: Healthy; Memory Impairment

Treatments: Drug: AZD8529; Drug: Placebo to match AZD8529

Study type: Interventional

Funder types: Industry

Identifiers

NCT00985933

D2285M00015

Details and patient eligibility

About

The purpose of this study is to assess if ketamine will induce, in healthy volunteers, impairment of working memory and if the drug AZD8529 will block the effects of ketamine on working memory as assessed by functional magnetic resonance imaging (fMRI).

Enrollment: 20 estimated patients

Sex: All

Ages: 21 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Right handed
• 12th grade education or equivalent
• Able to read and write English as primary language

Exclusion criteria

• History of head injury
• Substance abuse or dependence
• History of claustrophobia

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

20 participants in 3 patient groups, including a placebo group

1

Experimental group

Description:

180 mg of AZD8529

Treatment:

Drug: Placebo to match AZD8529

Drug: AZD8529

2

Experimental group

Description:

50 mg AD8529

Treatment:

Drug: Placebo to match AZD8529

Drug: AZD8529

3

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo to match AZD8529

Drug: AZD8529